Nirsevimab Safety: Side Effects & Clinical Trial Data

Nirsevimab has an unusually clean safety record for a drug given to newborns. Across every completed randomized trial, the rate of serious side effects in babies who received nirsevimab was the same as, or slightly lower than, the rate in babies who received a placebo. The most common complaint is a mild reaction at the injection site, and severe allergic responses have been vanishingly rare. But “safe in trials” and “safe in the real world” are different conversations, and enough post-licensure data has now accumulated to start having both.

How Nirsevimab Works and Why That Matters for Safety

Nirsevimab is a monoclonal antibody, not a vaccine. It does not stimulate your baby’s immune system to produce its own antibodies. Instead, it provides ready-made antibodies that latch onto the RSV virus’s fusion protein and block it from entering airway cells. The antibody targets a highly conserved spot on the virus called site Ø, which the virus exposes only in its pre-fusion shape.¹

The reason a single shot lasts an entire RSV season comes down to an engineering tweak in the antibody’s structure. Researchers introduced three amino acid changes in the antibody’s tail region that make it cling more tightly to a recycling receptor inside cells. Instead of being broken down quickly, the antibody gets shuttled back into the bloodstream over and over, extending its average half-life to about 71 days.² This matters for safety because that same engineering means the body does eventually clear the drug on its own. There is no permanent alteration, no genetic change, and no lasting immune activation. The antibody circulates, does its job for several months, and fades.

What the Pivotal Trials Found

The trial that carried nirsevimab to approval in healthy late-preterm and full-term infants was called MELODY. It enrolled roughly 1,500 babies, two-thirds of whom received nirsevimab and one-third a placebo. By day 361, serious adverse events had been reported in about 6.8% of the nirsevimab group compared with 7.3% of the placebo group.³ In other words, the babies who got the drug actually had a slightly lower rate of serious problems than those who got nothing, though the difference was small enough to be statistical noise. The point is that nirsevimab did not add to the baseline rate of serious events in a healthy infant population.

An earlier trial focused specifically on preterm infants (born at 29 to 34 weeks of gestation) and found a similarly reassuring picture: adverse events were comparable between the nirsevimab and placebo groups, with no notable hypersensitivity reactions.⁴

For higher-risk babies, including those with chronic lung disease or congenital heart disease, a separate trial called MEDLEY compared nirsevimab head-to-head with palivizumab, the older monthly-injection antibody that had been the standard of care for high-risk infants. Nirsevimab showed a similar safety profile to palivizumab in that population.⁵ Drug exposure levels in babies with chronic lung disease, congenital heart disease, or extreme prematurity were above the protective target in the vast majority of cases, suggesting the drug works as intended in these vulnerable groups without requiring dose escalation that might introduce new risks.⁶

The Most Common Side Effect Is a Sore Spot

Like most injections, the top complaint with nirsevimab is a reaction at the injection site: redness, swelling, or tenderness where the needle went in. In a large Canadian post-licensure surveillance study of over 1,500 children, local injection-site reactions were reported in about 9% of recipients overall. The rate was higher when nirsevimab was given alongside routine vaccines (about 17%) compared with when it was given alone (roughly 6%).⁷ These reactions were overwhelmingly mild. Swelling that extended beyond the nearest joint, which would signal a more significant local reaction, occurred in fewer than one in 250 children in that study.

Low-grade fever within a day of the injection was also reported in a small number of babies across trials, and it resolved quickly without treatment. Beyond injection-site soreness and transient fever, no pattern of common side effects has emerged that distinguishes nirsevimab recipients from babies who received a placebo or another product.

Severe Allergic Reactions and Other Serious Concerns

The fear that keeps any parent up at night is anaphylaxis or a serious allergic reaction. Across all the pivotal randomized trials, researchers tracked a predefined list of “adverse events of special interest,” which included hypersensitivity, anaphylaxis, thrombocytopenia (an abnormal drop in blood platelets), and immune complex disease. Every one of these occurred at a rate below 1%. No anaphylaxis was attributed to nirsevimab. No immune complex disease was reported in any trial. The handful of hypersensitivity events that did occur were generally inconsistent with true immediate-type allergic reactions, meaning they looked more like unrelated skin findings than drug-triggered responses.⁸

In the large HARMONIE trial, which enrolled over 8,000 infants, treatment-related adverse events were reported in about 2% of the nirsevimab group.⁹ That figure includes all events investigators judged to have a possible link to the drug, most of which were mild. The gap between “81% of participants had at least one adverse event” (the raw number you sometimes see quoted) and “2% had a treatment-related event” reflects a key distinction: babies get sick often in their first year regardless of what drug they receive. The trial’s job is to sort out which events are plausibly connected to nirsevimab and which are just the normal background of infant illness.

Anti-Drug Antibodies

Any time you introduce a lab-made protein into the body, there is a chance the immune system will recognize it as foreign and produce antibodies against it, known as anti-drug antibodies. In the MELODY trial, these showed up in about 6% of nirsevimab recipients by day 361, compared with about 1% of the placebo group.³ That sounds like it could be a problem, but context matters. The presence of anti-drug antibodies does not automatically mean the drug stops working or causes harm. In the trials, babies who developed these antibodies did not have higher rates of side effects or allergic reactions.

In immunocompromised children, the rate was somewhat higher. In the MUSIC trial, about 11% of participants developed treatment-emergent anti-drug antibodies through day 361. None of those children had treatment-related serious adverse events, and the antibodies were not linked to hypersensitivity. What they did seem to affect was drug clearance: children who developed these antibodies were more likely to have undetectable nirsevimab levels by day 361, raising the theoretical concern that protection might wane earlier in that small subset.¹⁰ For most families, anti-drug antibodies are a pharmacology detail rather than a practical worry, but it is one reason researchers continue to monitor long-term data.

Safety in Immunocompromised Children

Children undergoing chemotherapy, organ transplant recipients on immunosuppressive drugs, and babies with primary immune deficiencies represent a population where any new treatment warrants extra caution. The open-label MUSIC trial enrolled 100 immunocompromised children aged 24 months or younger and tracked them for a full year. About 81% experienced at least one adverse event during follow-up, but that high headline number reflects the reality that immunocompromised children are frequently hospitalized for infections and complications unrelated to any study drug.

Only six children (6%) experienced events the investigators judged as treatment-related, and all were mild: mostly brief fevers and a couple of skin rashes that resolved on their own. Thirty-two percent had at least one serious adverse event, and 31% had a severe event (grade 3 or higher), but none of these were considered related to nirsevimab. Three deaths occurred during the study, caused by a bacterial lower respiratory tract infection, septic shock from Klebsiella, and suspected tumor hemorrhage. Independent reviewers determined that none were connected to the drug.¹⁰ The finding that nirsevimab does not appear to worsen outcomes in this fragile population is significant, since these are precisely the children who face the highest risk from RSV itself.

Giving Nirsevimab Alongside Routine Vaccines

A common practical question is whether nirsevimab can be given at the same visit as routine childhood immunizations. The answer from both clinical trial data and the CDC’s Advisory Committee on Immunization Practices is yes. In trials where co-administration was studied, the rate of adverse events was similar to what would be expected from the vaccines alone. Because nirsevimab is a passive antibody rather than a vaccine, it does not engage the infant’s adaptive immune system the way a vaccine does, so there is no biological reason to expect interference with vaccine responses.¹¹

That said, the Canadian post-licensure data noted earlier did show a higher rate of injection-site reactions when nirsevimab was co-administered with other vaccines (about 17% versus 6% when given alone).⁷ That bump likely reflects the added local inflammation from multiple injections at one visit rather than a drug interaction. For families trying to minimize the number of office visits, simultaneous administration remains the recommended approach.

Re-dosing for a Second RSV Season

Most healthy infants only need nirsevimab for their first RSV season. But children with chronic lung disease or congenital heart disease sometimes remain vulnerable enough to warrant a second season of protection. In the MEDLEY trial’s extension, children in these high-risk groups who received a 200 mg dose of nirsevimab before their second season showed a safety profile similar to that of children who received palivizumab as their second-season comparator.¹² The drug achieved blood levels consistent with the protective range seen in earlier efficacy trials, and no new safety signals emerged from the second dose. For children with congenital heart disease who underwent cardiopulmonary bypass surgery, which can wash out circulating antibodies, replacement dosing was also studied with no post-baseline anti-drug antibody development or hypersensitivity events observed in those who received it.⁸

How Does Nirsevimab Compare to Palivizumab in Adverse Event Reports?

Palivizumab has been used since the late 1990s, so it has a two-decade head start in real-world safety data. An analysis of the FDA’s post-marketing adverse event reporting system (FAERS) compared reports filed for both drugs. Among roughly 2,000 qualifying reports (1,380 for palivizumab, 641 for nirsevimab), the patterns diverged in interesting ways. Nirsevimab reports were more likely to include skin reactions and procedural complications, while palivizumab reports were more likely to flag infections, gastrointestinal problems, and respiratory issues.¹³

This kind of comparison requires careful interpretation. FAERS is a voluntary reporting system, and the populations who receive each drug are different: palivizumab is restricted to high-risk infants, while nirsevimab is recommended broadly. The higher rate of “injury, poisoning, and procedural complications” in nirsevimab reports could reflect medication errors early in rollout, such as dosing mix-ups, rather than true drug toxicity. The lower rate of infections and respiratory complaints in the nirsevimab column probably reflects the healthier baseline population receiving it. These numbers are useful for generating hypotheses and flagging potential signals, but they do not prove one drug is safer than the other in a controlled sense.

Nirsevimab vs Maternal RSV Vaccination

Parents of newborns now face a choice that did not exist until recently: protect the baby with nirsevimab given after birth, or have the mother receive the RSVpreF vaccine during pregnancy so that protective antibodies cross the placenta before delivery. A large observational study comparing the two strategies in real-world U.S. data found that nirsevimab was associated with a lower risk of RSV-related hospitalization than the prenatal vaccine. The adjusted hazard ratio was 0.74, meaning infants who received nirsevimab had about a quarter less risk of RSV hospitalization compared with those whose mothers received the vaccine. For the most severe outcomes, including ICU admission, need for a ventilator, and need for supplemental oxygen, the advantage was even larger, with risk reductions approaching 40 to 44%.¹⁴

This comparison is about effectiveness rather than side-effect profiles, but it has practical safety implications. The maternal vaccine carries its own set of concerns, including a potential signal around preterm birth that prompted regulatory scrutiny. Nirsevimab sidesteps that issue entirely because it is given after the baby is born. For families weighing the two options, the question is not just “which has fewer side effects” but “which delivers more protection against a virus that hospitalizes tens of thousands of infants each year.” The available evidence tilts toward nirsevimab on both counts, though both strategies are considered acceptable by advisory bodies.

What Post-Licensure Surveillance Is Showing

Clinical trials, no matter how well designed, study thousands of children at most. Rare side effects that occur in one in ten thousand or one in fifty thousand recipients can only be detected once millions of doses have been given. That is the role of post-licensure surveillance systems like the Canadian CANVAS network, the U.S. Vaccine Adverse Event Reporting System (VAERS), and the FAERS database.

The Canadian data from over 1,500 children found no serious safety signals beyond the expected injection-site reactions.⁷ That is reassuring, but the sample is still relatively modest for catching very rare events. Surveillance will need to continue through multiple RSV seasons before the full real-world safety picture is clear. The pooled clinical trial analysis, which combined data across all pivotal studies, found no anaphylaxis attributed to the drug and no immune complex disease, and the few thrombocytopenia events that occurred were linked to other causes like heparin use during surgery or concurrent infections.⁸

The picture so far is one of a drug that does what it is supposed to do without introducing meaningful new risks, even in medically fragile populations. That is a high bar for any product given routinely to healthy newborns, and the data across both controlled trials and early real-world use consistently clears it. As more countries roll out nirsevimab programs and surveillance databases grow, the confidence intervals around rare-event estimates will tighten. For now, the absence of any serious safety signal after millions of global exposures is itself a strong form of evidence.

1
Journal of Antimicrobial Chemotherapy. Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants
2
PubMed Central. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection
3
PubMed. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
4
PubMed. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
5
The Lancet Child & Adolescent Health. Nirsevimab efficacy in infants born between 29 weeks’ gestation and full term and extrapolation to high-risk infants: a pooled analysis of randomised controlled trials
6
PubMed Central. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
7
PubMed Central. Post-licensure safety of nirsevimab from the Canadian National Vaccine Safety (CANVAS) network
8
PubMed Central. Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials
9
PubMed. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants
10
Pediatrics. Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children
11
MMWR. Morbidity and Mortality Weekly Report. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
12
PubMed Central. Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease
13
PubMed Central. Comparative Analysis of Reported Adverse Events with Nirsevimab and Palivizumab in the FAERS Database
14
PubMed Central. Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in Newborns